Term ends Aug 31, 2032 · High confidence
20-year base term ends Aug 31, 2032
Held by Regeneron Pharmaceuticals, Inc.
Filed Jan 7, 2014 as application 14/149,520 · Granted Dec 29, 2015
Base term, 20 years from filing
Today
2012
2032
Clock starts
Aug 31, 2012
Aug 31, 2012
Term ends
Aug 31, 2032
Aug 31, 2032
Granted
Dec 29, 2015
Dec 29, 2015
base term
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
2
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 31, 2012, when application 13/601,023, the earliest non-provisional in its chain, was filed (this one was filed Jan 7, 2014) | Aug 31, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 31, 2032 | High confidence |
This family
| US 8,710,180 | In force Aug 2032 | Aug 2032 |
| US 9,221,889 | this patent Aug 2032 | Aug 2032 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 15, 2015 Reel 36565, frame 168 | Pitram, Suresh Mark; Agnew, Heather Dawn; Lai, Tsun Yin; Rohde, Rosemary Dyane; Kearney, Paul Edward | Integrated Diagnostics, Inc. | Assignment of Assignor's Interest |
| Sep 15, 2015 Reel 36565, frame 240 | Law, Scott; Fang, Kenneth Charles | Integrated Diagnostics, Inc. | Assignment of Assignor's Interest |
| Sep 15, 2015 Reel 36565, frame 270 | Integrated Diagnostics, Inc. | Indi Molecular, Inc. | Assignment of Assignor's Interest |
| Oct 26, 2023 Reel 65356, frame 723 | Indi Molecular, Inc. | Regeneron Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Aug 2032
Term ends Aug 31, 2032. Maintenance fees still fall due before then
Citations
9
later US patents cite this one
That is above the median of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.